论文部分内容阅读
目的 评价曲美他嗪对缺血性心脏病、心绞痛的临床疗效。方法 缺血性心脏病心绞痛病人118例 ,随机分为A、B两组 ,A组给予常规治疗 ;B组在常规治疗基础上加服曲美他嗪 2 0mg ,1日 3次 ,并观察下述指标 :①静息心电图 ;②心绞痛发作的次数 ;③心绞痛发作持续的时间 ;④不良反应。结果 B组可明显改善静息心电图心肌缺血的表现 ,总有效率为 80 3 % ,与A组比较差异有显著意义 (P <0 0 5) ;B组能缓解心绞痛发作的次数及缩短心绞痛的持续时间 ,与A组比较差异有显著意义 (P <0 0 5)。结论 曲美他嗪作为心肌细胞能量代谢优化剂 ,使用安全 ,值得临床推广。
Objective To evaluate the clinical efficacy of trimetazidine on ischemic heart disease and angina pectoris. Methods 118 patients with ischemic heart disease and angina pectoris were randomly divided into two groups A and B. Group A received routine treatment. Group B received trimetazidine 20 mg on the basis of conventional treatment, three times a day, and observed The indicators: ① resting ECG; ② the number of angina attacks; ③ angina pectoris duration; ④ adverse reactions. Results Group B significantly improved myocardial ischemia at resting electrocardiogram, with a total effective rate of 80.3%, which was significantly different from that of group A (P <0 05). Group B could relieve the number of angina pectoris and angina pectoris Of the duration, compared with the A group was significant (P <0 05). Conclusion Trimetazidine as a cardiomyocyte energy metabolism optimization, the use of safe, worthy of clinical promotion.